He is a Professor in pharmacology department of Uiversity of Illinois, Chicago

Recovery of endothelial barrier integrity after vascular injury is vital for endothelial barrier function and vascular homeostasis. Endothelial dysfunction plays a critical role in the initiation and progression of vascular diseases such as acute lung injury/acute respiratory distress syndrome, and atherosclerosis. A part of the research in the lab is to elucidate the molecular mechanisms of endothelial regeneration and restoration of endothelial barrier integrity following inflammatory lung vascular injury, understand the mechanisms of action of stem/endothelial progenitor cells-mediated endothelial regeneration, vascular repair, and neovascularization using the unique mouse model with endothelial cell-restricted deletion of FoxM1 (JCI, 116:2333-43, 2006; JEM, 207:1675-85, 2010) and other genetically modified animal models

Esmaiel Jabbari completed his PhD at Purdue University and postdoctoral studies at Monsanto, Rice University, and Mayo Clinic. He is Full Professor of Chemical and Biomedical Engineering and Director of Biomimetic Materials and Tissue Engineering Laboratory at University of South Carolina. He is internationally known for his work on synthesis and processing of cell-responsive polymers and hydrogels for applications in tissue engineering and regenerative medicine. He received the Berton Rahn Award from the AO Foundation in 2012 and the Stephen Milam Award from the Oral and Maxillofacial Surgery Foundation in 2008. He was elected to the College of Fellows of the American Institute for Medical and Biological Engineering (AIMBE) in 2013. He has published >230 books, book chapters, peer-reviewed journal articles, and conference proceedings, and presented >260 seminars at national and international conferences on biomaterials, tissue engineering, and drug delivery. He has mentored >130 visiting scholars, post-doctoral researchers, doctoral students, and undergraduate students. He is a member of numerous scientific organizations including BMES, SFB, TERMIS, MRS, EMBS, ACS, AIChE, and AACR.

.

Diana is director of the Anderson University Center for Cancer Research and is excited about the research opportunities it can offer, as well as the local internships she can refer students to.She is a Director of Education at Susan G. Komen Mountains to Midlands Affiliate.

Biology, Cellular Biology, Genetics, Microbiology

Roger R. Markwald, Ph.D., MUSC Cell Biology and Anatomy Department chairman and professor, received the American Association of Anatomy’s highest scientific accolade on April 5 during its annual meeting in San Diego. The Henry Gray award was co-sponsored by the American Association of Anatomists and Lippincott Williams & Wilkins, which recognizes unique and meritorious contributions and achievements in the field of Anatomical Sciences by a distinguished AAA member.

My laboratory has pursued studies on the cell and molecular mechanisms of heart development that utilized in vivo dynamic labeling studies to demonstrate that heart development is progressive, irreversible and occurs by the addition of new segments including ones derived from extracardiac sources. Three dimensional culture assays were also developed that faithfully recapitulated in vivo morphogenetic processes which permitted identification of: (1) a novel heart forming field that gave origin to the outflow track at the arterial pole of the heart (, (2) specific growth factors of the TGFβ supergene as inducers of the outflow track and the transformation of specific populations of endothelial cells into multiple progenitor cells of internal partitions that divide the heart into right and left sides a and their respective valves and (3) specific matricellular proteins (periostin and CCN1,2) as ligands that activate integrin-linked, nodal intracellular kinase pathways in valvuloseptal progenitor cells that promote their differentiation into fibroblasts and regulate cytoskeletal changes that promote their remodeling into sculpted leaflets. Modifications of the culture system have also permitted the functional assessment of the viscoelastic properties of developing valves and the role of biomechanical signaling in cardiac cell and matrix differentiation.

.

He Controlled cardiac lineage differentiation of embryonic stem cells, iPSCs & adult cardiac stem cells, iPSC reprograming and characterization Electrophysiological and functional maturity of stem cell-derived cardiomyocytes, Stem cell tissue engineering and Applications and mechanisms of stem cell-based therapy for cardiovascular diseases

Dr. Mironov studied Medicine at the Ivanovo Sate Medical University, Ivanovo, Russia and graduated as MD in 1977. He received his PhD degree in Developmental Biology 1980 at the Moscow Pirogov State Medical Institute in 1980. After that he worked at different position in Germany, USA and Brazil. Last 5 years he serves as Chief Scientific Officer of private bioprinting company 3D Bioprinting Solutions, Moscow, Russia. He bioprinted world first functional vascularized mouse organ – mouse thyroid gland in 2015 and bioprinted a first 3D tissue (human cartilage) in Space at the International Space Station in December of 2018.

3D Bio printing, 3D Tissue regeneration

José Luis Carrillo Gamboa has completed his PhD from National Autonomous University of México in the School of Medicine. He is the Director and Founder of Mexico. He is an Academic Coordinator in Orthopedics at Hospital H+ Querétaro and; advisory member of University of Valley of México. He has published results in osteoarthritis with stem cells.

Regenerative Medicine, 3D Bio printing

Dr Kampon Sriwatanakul is the president of Vita Stem Co. Ltd., Bangkok and an internationally recognized pioneer of stem cell therapy. He is currently engaged in research and development projects related to the application of mesenchymal stem cell in the anti-aging and regenerative medicine.

Stem Cell Therapy, Regenerative Medicine

Alain Chapel is a Scientific Investigator at IRSN, Laboratory of Radiopathology and Experimental Therapies.For 25 years, he has been developing gene and cell therapy using non-human primates, immune-tolerant mice and rats to protect against the side effects of radiation. He collaborates with clinicians to develop strategies for treatment of patients after radiotherapy overexposures. He has participated in the first establishment of proof of concept of the therapeutic efficacy of Mesenchymal stem cells (MSCs) for the treatment of hematopoietic deficit, radiodermatitis and over dosages of radiotherapy. He has contributed to the first reported correction of deficient hematopoiesis in patients (graft failure and aplastic anemia) thanks to intravenous injection of MSCs restoring the bone marrow microenvironment, mandatory to sustain hematopoiesis after total body irradiation. He is scientific investigator of Clinical phase II trial evaluating the efficacy of systemic MSC injections for the treatment of severe and chronic radiotherapy-induced abdomino-pelvic complications refractory to standard therapy (NCT02814864Hirsch Index 26.

Regenerative medicine, Cell therapy, scaffold, radiotherapy

Dr.Omid Panahi , Graduated from Centro Escolar University on 2013 in field of Doctor of Dental Mediciene( DMD), and MSc Oral and maxillofacial surgery at yeditepe university, Istanbul, turkey. He has published more than 40 papers in reputed journals and has been serving as an editorial board member of isi journals.

Oral implant, Oral surgery, Regenerative dentistry

Peter A. Everts is the Chief Scientific Officer at EmCyte Corporation with a demonstrated history of working in the medical practice industry. He is Skilled in Medical Devices for biological therapies for use in Orthobiology-MSK, Spine, Chronic Wound Care, Cardiac Surgery, Reconstructive Surgery, Facial Aesthetics, Hair Regrowth, and other Regenerative Medicine applications.Peter A. Everts is an Strong research professional graduated from the University of Utrecht PhD program, and International ATMO, San Antonio, TX, USA.

Regenerative Medicine, Tissue Regeneration, Platelet Rich Plasma, bone marrow and adipose mesenchymal cells

He was born in 1947, education in mechanical engineering / textile technology at University of Stuttgart (Germany), 1974 Scientist Institute for Textile and Process Engineering (ITV Denkendorf) 1980 – 1998 Supervisor Biomedical Engineering Group, 1998 Director of ITV and Full Professor for Textile Technology / Biomedical Engineering, add. 2001 CEO ITV Product Service GmbH, 2006 Director Interuniversital Center for Biomedical Engineering Stuttgart-Tuebingen, Vicepresident and President German Soc. for Biomaterials Member of the Coucil Europ. Soc. Biomaterials Director and Member of the Board of several Center of Excellences Biomedical Engineering

bio materials for soft tissue replacement, Implants, artificial organs, tissue engineering, wound care

Denis Barritault graduated in Math and Physics, completed his Ph.D. in biochemistry in Paris University. Post doctoral in molecular immunology at Pasteur Institute and NYU as NIH Fogarty Fellow he joined INSERM unit in Paris as developmental biologist. He made the first description and patents of FGF extracted from retina in 1979 and 82 as skin and cornea healing agent, became full professor at Paris East University in 1985, founded and directed a CNRS Laboratory on cell and tissue regeneration until 2003. He is now President of OTR3, Emeritus Professor and author in over 200 publications and 29 patents.

tissue regeneration, molecular immunology

Professor Oleksandr Kukharchuk, M.D. (Doctor of Medical Science) has accomplished 15 yrs of progenitor cells therapy experience in Ukraine, and 7 yrs in India. Scientific Publications: 250, patents: 17. He developed regulatory documents for stem cells therapy to implement as official treatment in Ukraine. Has innovated technique, how to overcome biggest challenge in transplantation – “Rejection of foreign tissue”. Prof. Oleksandr Kukharchuk guided clinical trials for evaluation of progenitor cells transplantation efficacy in diabetes mellitus, chronic limb ischemia, myocardiodystrophy, liver cirrhosis, male infertility, aging and pancreonecrosis. He is author of the book “Stem cells: Experiment, Theory, Clinic. Embryonic, mesenchymal, neural, hematopoetic stem cells”. Approval Committee member of Health Ministry “Program of transplantation in Ukraine” 2006-2010, Director of Coordination Centre for Organs, Tissues and Cells Transplantation of the Ukraine Health Ministry, 2006-2010; Member of European Society of Transplantology from 2006; Member of European Society of Gene and Cell Therapy from 2012.

Biotechnology & Regenerative Medicine: stem cells 3D culture, stem cells exosomes, stem cells growth factors

Yaegaki K is a Doctor of Dental Science. He has completed his PhD in Medicine from Kureme University Medical Biochemistry and Post-doctoral studies from University of British Columbia. He was trained as Oral Maxillofacial Surgeon at School of Medicine Kurume University. His specialty was facial injuries and cancer. He is the Director and Head of Oral Health at Nippon Dental University, which is the oldest dental school in Asia, also a Dean of PhD program. He has published more than 100 papers and 20 books. He has been serving as an Editorial Board Member of repute.

stem cell research, regenerative medicine, tissue engineering etc

Takashi Tsuji has completed PhD from Niigata University and worked in JT Inc. He was Professor of Tokyo University of Science (2000-14) and is Team leader of RIKEN BDR (2014-Present). He is Visiting Professor of Kobe University, Tokyo Dental University, Kwansei University, Tokyo University of Science and Keio University. He has published more than 100 papers including review in journals and has been serving as an editorial board member of Scientific Reports. He is a Director of Organ Technologies Inc.

Regenerative Medicine, Organ Regeneration

Xiao-Dong Chen, M.D., Ph.D. is a Professor (tenured) in the Department of Comprehensive Dentistry and Chief of the Regenerative Medicine Program in the School of Dentistry at the University of Texas Health Science Center at San Antonio. Dr Chen’s group was the first to establish a culture system, using cell-free native ECM made by bone marrow stromal cells, for rapidly growing large numbers of high-quality non-hematopoietic stem cells (NHSCs) from various sources, including bone marrow and umbilical cord blood. To closely replicate the tissue specific microenvironment (niche) ex vivo, Dr. Chen and his team have extended their technology by developing a variety of 3D tissue-specific scaffolds for facilitating stem cell-based applications such as: 1) rejuvenating NHSCs from the elderly to establish a personal stem cell bank with large numbers of high-quality autologous cells for treating age-related diseases; 2) inducing NHSC differentiation into the salivary gland epithelial cell lineage for repairing damaged salivary gland; and 3) enhancing the efficacy of bone marrow-derived MSCs for treating community-acquired pneumonia. The cell culture technology has also been found to have other applications such as preserving pancreatic islet function, while reducing islet immunogenicity, for use in allograft transplantation to treat type I diabetes. Based on knowledge gleaned from studies of native tissue-specific ECMs (TS-ECMs), Dr. Chen’s group has been actively working on developing a series of defined tissue-specific ECMs to selectively control NHSC fate so that a homogenous population of committed cells (muscle, bone, cartilage, skin, etc) can be obtained for tissue regenerative purposes. To foster the translation of his laboratory discoveries, Dr. Chen co-founded a startup company in 2010 (StemBioSys, Inc.; www.stembiosys.com). During the last several years, the company has been developing technology for scaling up the production of stem cells for treating human diseases, and providing a unique platform for quickly developing broad collaborations with other research institutes and biotech companies for basic research and clinical applications.

Reconstitute tissue-specific stem cell niche in vitro to control stem cell fate for tissue regenerative purposes.

Dr. Purita is director of Institute of Regenerative and Molecular Orthopedics (www.stemcellorthopedic.com) in Boca Raton, Florida. Dr. Purita is a pioneer in the use of Stem Cells and Platelet Rich Plasma. He received a B.S. and MD degree from Georgetown Univ. Dr. Purita is board certified in Orthopedics by ABOS. He is a Fellow American College of Surgeons, Fellow American Academy Orthopedic Surgeons, and a Fellow American Academy of Pain Management. He has lectured and taught extensively throughout the world on the use of Stem Cells and Platelet Rich Plasma. He has helped countries develop Stem Cell policies.

Stem cell,regenerative medicine

lain Chapel is a Scientific Investigator at IRSN, Laboratory of Radiopathology and Experimental Therapies.For 25 years, he has been developing gene and cell therapy using non-human primates, immune-tolerant mice and rats to protect against the side effects of radiation. He collaborates with clinicians to develop strategies for treatment of patients after radiotherapy overexposures. He has participated in the first establishment of proof of concept of the therapeutic efficacy of Mesenchymal stem cells (MSCs) for the treatment of hematopoietic deficit, radiodermatitis and over dosages of radiotherapy. He has contributed to the first reported correction of deficient hematopoiesis in patients (graft failure and aplastic anemia) thanks to intravenous injection of MSCs restoring the bone marrow microenvironment, mandatory to sustain hematopoiesis after total body irradiation. He is scientific investigator of Clinical phase II trial evaluating the efficacy of systemic MSC injections for the treatment of severe and chronic radiotherapy-induced abdomino-pelvic complications refractory to standard therapy (NCT02814864Hirsch Index 26.

Regenerative medicine, Cell therapy, scaffold, radiotherapy

Kara E. McCloskey, PhD, is a Founding and Associate Professor in the School of Engineering at the University of California, Merced. She received her BS and an MS in Chemical Engineering from The Ohio State University and her PhD through a joint program with Cleveland Clinic Foundation’s Biomedical Engineering Department and Ohio State University. She then completed her postdoctoral training in vascular stem cell and tissue engineering with Dr. Robert Nerem at the Georgia Institute of Technology. Her research is in the field of cardiovascular tissue engineering with a specific focus on deriving functional cell products from stem cells. Dr. Kara McCloskey has over 15 years of experience in the area of endothelial cell (EC) fate and cardiovascular tissue engineering.

Tissue Engineering,Cell therapy,Stem cells,Regenerative Medicine

Véronique Migonney received an Engineer Diploma in Materials Science (1981), a Master in Biomedical and Biomaterials Engineering (1982) and a PhD (1986) in Chemistry (Doctorate of State Es Physics specialty Chemistry - Supervisor M. Jozefowicz) from University Paris 13th. Véronique Migonney was director of the laboratory CSPBAT UMR 7244 CNRS UP13 from 2009 to 2016 and heads the team LBPS devoted to Biomaterials Sciences from 2002. She is a graduate of the Master of Chemistry and Health Engineering from 2004 to 2016. Véronique Migonney is Fellow of The International College of Fellows in Biomaterials Science and Engineering for its contribution to the functionalization of biomaterials surfaces. She was president of the French Society for Biomedical Engineering 2011-2013 and she is vice-president of the AGBM (Alliance for Biological and Medical Engineering). Her expertise is focused on biomaterials science: she is working for> 35 years in the field of bioactive polymers synthesis and grafting to functionalize biomaterials surfaces with the aim of controlling the response.

bio materials,bio medical engineering

Shaik O. Rahaman, PhD, is an Assistant Professor in the Department of Nutrition and Food science at the University of Maryland, USA. His laboratory is interested in elucidating the molecular signaling events underlying the pathogenesis of various inflammatory diseases, specifically, atherosclerosis and fibrosis. Dr. Rahaman earned his PhD in Molecular Biology at Jadavpur University, and a BS in Human Physiology (Honors), and an MS in Biophysics and Molecular Biology from University of Calcutta. From 2000-2014, Dr. Rahaman worked at Cleveland Clinic, Cleveland, USA, as a Postdoctoral Fellow, eventually as a Project Scientist studying signal transduction in Cell Biology and Oncology. He has received many awards and honors. Dr. Rahaman was honored with Elsa Albrecht Award by Cleveland Clinic, which is awarded for outstanding publication. During 2011-2014, Dr. Rahaman also served as an Assistant Professor at Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, USA. In 2013, he was the recipient of the American Heart Association Scientist Development Grant. Dr. Rahaman is the author or co-author of 20 research papers on neurobiology, oncology, atherosclerosis, or fibrosis in high impact international peer-reviewed journals of repute including Cell Metabolism and Journal of Clinical Investigation. Dr. Rahaman has given numerous invited talks nationally and internationally, and is a reviewer/editorial board member in numerous scientific journals. Dr. Rahaman also served as a reviewer for National Institute of Health (USA).

Cell Biology and Oncology

Dr. Rajput is a consultant orthopaedics and stem cell transplant surgeon practicing for the last 33 years. He has been trained in orthopaedic surgery and stem cell transplantation at various national and international medical centres of repute. He has also received specialised training at Royal Liverpool University Hospital, Liverpool, U.K. In the last 5 years he has developed & established Stem Cell Transplantation as a new branch of medical science in India. He has also the credit of performing more than 2000 stem cell transplants till date. Dr. Rajput has shown the definitive results of Stem Cell Transplantation in various diseases, specially in the cases of Duchenne Muscular Dystrophy, Degenerative Arthritis of the Knee, Autism, CP, and Spinal Cord Injuries. He is also the pioneer in bringing other cell based therapies like T-Cell Immunotherapy and Dendritic Cell vaccine in India for resistant cases of Cancer where chemotherapy & Radiotherapy has failed.

Stem Cell Transplantation,Regenerative Medicine,Tissue Engieering.

Maria Cristina Tanzi had her Master Degree in Chemistry and Pharmaceutics, Milano University, in 1975 (with honors). From 1980 to 1989, she was Assistant Professor of Applied Chemistry at the Industrial Chemistry Department and from 1990 to 1998 at the Bioengineering Department, Politecnico di Milano,. From 1999 to 2007 she was Associate Professor of Chemical Bioengineering, from 2008 to 2012 she was Full Professor at the Bioengineering Department, and starting 2013 (until March 1st, 2014) at the Chemistry, Materials and Chemical Engineering Department of Politecnico di Milano.

Bio Materials,Tissue Engineering,Regenerative Medicine

He is a Professor in pharmacology department of Uiversity of Illinois, Chicago

Recovery of endothelial barrier integrity after vascular injury is vital for endothelial barrier function and vascular homeostasis. Endothelial dysfunction plays a critical role in the initiation and progression of vascular diseases such as acute lung injury/acute respiratory distress syndrome, and atherosclerosis. A part of the research in the lab is to elucidate the molecular mechanisms of endothelial regeneration and restoration of endothelial barrier integrity following inflammatory lung vascular injury, understand the mechanisms of action of stem/endothelial progenitor cells-mediated endothelial regeneration, vascular repair, and neovascularization using the unique mouse model with endothelial cell-restricted deletion of FoxM1 (JCI, 116:2333-43, 2006; JEM, 207:1675-85, 2010) and other genetically modified animal models

Esmaiel Jabbari completed his PhD at Purdue University and postdoctoral studies at Monsanto, Rice University, and Mayo Clinic. He is Full Professor of Chemical and Biomedical Engineering and Director of Biomimetic Materials and Tissue Engineering Laboratory at University of South Carolina. He is internationally known for his work on synthesis and processing of cell-responsive polymers and hydrogels for applications in tissue engineering and regenerative medicine. He received the Berton Rahn Award from the AO Foundation in 2012 and the Stephen Milam Award from the Oral and Maxillofacial Surgery Foundation in 2008. He was elected to the College of Fellows of the American Institute for Medical and Biological Engineering (AIMBE) in 2013. He has published >230 books, book chapters, peer-reviewed journal articles, and conference proceedings, and presented >260 seminars at national and international conferences on biomaterials, tissue engineering, and drug delivery. He has mentored >130 visiting scholars, post-doctoral researchers, doctoral students, and undergraduate students. He is a member of numerous scientific organizations including BMES, SFB, TERMIS, MRS, EMBS, ACS, AIChE, and AACR.

.

Professor Fariba Dehghani Director of ARC Biotechnology and Food Processing Training Centre, Director of Bioengineering Research, School of Chemical and Biomolecular Engineering Professor Fariba Dehghani's work in bioengineering research focuses on developing technologies for processing biomaterials, with particular emphasis on tissue engineering and regenerative medicine. Fariba's research aims to develop sustainable, low-energy, benign processes for manufacturing bio-products and to reduce organic solvent consumption.

Her research focuses on developing technologies for processing biomaterials, with particular emphasis on tissue engineering and regenerative medicine. "My research aims to develop sustainable, low-energy, benign processes for manufacturing bio-products and to reduce organic solvent consumption. For instance, currently I am looking into developing bio-inspired materials and technologies to engineer tissues and organs, and investigating whether these can translate to clinical outcomes. This involves novel materials and implant devices as well as compounds for the treatment and prevention of cardiovascular disease, viral infections, cancer, osteoporosis and a range of other health issues.

Diana is director of the Anderson University Center for Cancer Research and is excited about the research opportunities it can offer, as well as the local internships she can refer students to.She is a Director of Education at Susan G. Komen Mountains to Midlands Affiliate.

Biology, Cellular Biology, Genetics, Microbiology

Roger R. Markwald, Ph.D., MUSC Cell Biology and Anatomy Department chairman and professor, received the American Association of Anatomy’s highest scientific accolade on April 5 during its annual meeting in San Diego. The Henry Gray award was co-sponsored by the American Association of Anatomists and Lippincott Williams & Wilkins, which recognizes unique and meritorious contributions and achievements in the field of Anatomical Sciences by a distinguished AAA member.

My laboratory has pursued studies on the cell and molecular mechanisms of heart development that utilized in vivo dynamic labeling studies to demonstrate that heart development is progressive, irreversible and occurs by the addition of new segments including ones derived from extracardiac sources. Three dimensional culture assays were also developed that faithfully recapitulated in vivo morphogenetic processes which permitted identification of: (1) a novel heart forming field that gave origin to the outflow track at the arterial pole of the heart (, (2) specific growth factors of the TGFβ supergene as inducers of the outflow track and the transformation of specific populations of endothelial cells into multiple progenitor cells of internal partitions that divide the heart into right and left sides a and their respective valves and (3) specific matricellular proteins (periostin and CCN1,2) as ligands that activate integrin-linked, nodal intracellular kinase pathways in valvuloseptal progenitor cells that promote their differentiation into fibroblasts and regulate cytoskeletal changes that promote their remodeling into sculpted leaflets. Modifications of the culture system have also permitted the functional assessment of the viscoelastic properties of developing valves and the role of biomechanical signaling in cardiac cell and matrix differentiation.

.

He Controlled cardiac lineage differentiation of embryonic stem cells, iPSCs & adult cardiac stem cells, iPSC reprograming and characterization Electrophysiological and functional maturity of stem cell-derived cardiomyocytes, Stem cell tissue engineering and Applications and mechanisms of stem cell-based therapy for cardiovascular diseases

Dr. Harris is a graduate of Wake Forest University in Winston-Salem, North Carolina where he obtained Bachelor of Science degrees (cum laude) in Biology, Mathematics and Psychology in 1978. He earned a Masters of Medical Sciences (summa cum laude) from Bowman Gray Medical School in 1980 and his Doctorate in Microbiology and Immunology (magna cum laude) from Bowman Gray Medical School in 1982. From 1982-1985 Dr. Harris was a Post-doctorate Fellow at the Ludwig Institute for Cancer Research in Lausanne, Switzerland. In 1985 he joined the faculty at the University of North Carolina-Chapel Hill as a Research Assistant Professor in the Department of Medicine. In 1989 Dr. Harris joined the faculty at the University of Arizona in Tucson as an Associate Professor in the Department of Microbiology & Immunology. In 1996 Dr. Harris was promoted to Professor of Immunology. Dr. Harris established the first cord blood bank in the USA in 1992. He currently serves as the Executive Director of the University of Arizona Biorepository, Quality Director of the GMP Laboratory, is a member of the Arizona Cancer Center, a member of the Children’s Research Center, and a member of the Arizona Arthritis Center. Dr. Harris’s research interests include stem cells and regenerative medicine, cancer research/stem cell transplantation and gene therapy. Dr. Harris has founded 5 companies while at the University of Arizona; Cord Blood Registry, Inc.; ImmuneRegen BioSciences, Inc.; QuReGen, Inc., AdiCyte and Family Cryo Bank.

Banking of and research on stem cells and other tissues for discovery, regenerative medicine and cell therapy.

George Perry is dean of the College of Sciences and professor of biology at The University of Texas at San Antonio Perry is recognized in the field of Alzheimemiddot;s disease research particularly for his work on oxidative stress. Perry received his bachelormiddot;s of arts degree in zoology with high honors from University of California Santa Barbara After graduation he headed to Scripps Institution of Oceanography and obtained his PhD in marine biology under David Epel in 1979 He then received a postdoctoral fellowship in the Department of Cell Biology in the laboratories of Drs Bill Brinkley and Joseph Bryan at Baylor College of Medicine where he laid the foundation for his observations of abnormalities in cell structures

Alzheimer disease Oxidative stress Parkinson disease Cytoskeleton Mitochondria Amyloidosis Neuropathology Cytochemistry.

Study of Physics at the Moscow Institute of Physics and Technology (MIPT) (Moscow), PhD in Physics obtained from the MIPT and the P.N. Lebedev Physical Institute of the Russian Academy of Sciences in 1981. From 1981 to 1995, scientific employee at the P.N. Lebedev Physical Institute of the Russian Academy of Sciences in Moscow. In addition also assistant professor at the MIPT from 1987 to 1988. Professor Chichkov joined the Laser Zentrum Hannover e.V. (LZH) in 1995 and was a scientific employee until 1997. In 1997, he completed his habilitation at the University of Hannover (now: Leibniz Universität Hannover). From 1997 to 2000, associate professor at the Institute for Quantum Optics (IQ), University of Hannover. From 2001 to 2004, Head of the Strategy Group of the LZH. Since 2004, Professor Chichkov is Head of the Nanotechnology Department at the LZH and he obtained a W3 professorship for Nanoengineering at the IQ of the University of Hannover in 2009.

Applications of lasers in micro- and nanotechnology for photonics, plasmonics and biomedicine Multiphoton polymerization and development of novel photosensitive, bioactive and biodegradable functional materials as well as nano composites Latest laser technologies for the production of implants, tissue engineering and regenerative medicine

Dr. Murugan Ramalingam is Professor at the Centre for Stem Cell Research (a unit of the Institute for Stem Cell Biology and Regenerative Medicine-Bengaluru), Christian Medical College Campus, India. Concurrently he is Adjunct Professor at the Tohoku University, Japan. Prior to joining the CSCR, he was Associate Professor of Biomaterials and Tissue Engineering at the Institut National de la Santé et de la Recherche Médicale, Faculté de Chirurgie Dentaire, Université de Strasbourg, France. He has worked at the WPI Advanced Institute for Materials Research, Japan, as an Assistant Professor. He has also worked at the National Institute of Standards and Technology (NIST) and the National Institutes of Health (NIH), under the U.S. National Academies Associateship program. He received his Ph.D. in Biomaterials from the University of Madras. He has also undergone training in Ethical and Policy issues on Stem Cells from Harvard University, USA, and in Operations Management from the University of Illinois-Chicago. His current research interests are focused on the development of multiphase biomedical materials, through conventional to nanotechnology to biomimetic approaches, microfabrication, cell patterning, stem cell differentiation, tissue engineering and drug delivery. He is the author of over 250 publications, including peer-reviewed journal papers, conference proceedings, book chapters, authored books, edited books, and patents relevant to biomaterials, stem cells, and tissue engineering. His current h-index is 27 with over 5200 citations. He has organized several international conferences and chaired Biomaterials, Nanobiotechnology, Stem Cells and Tissue Engineering sessions. He also serves as a board member of several international scientific and research committees in various public and private bodies and grant reviewer of various international funding agencies. He serves on the editorial boards of multiple biomaterials and tissue engineering-related journals, including as the Editor-in-Chief of the Journal of Biomaterials and Tissue Engineering, the Journal of Bionanoscience and the American Journal of Stem Cell Research. He is a recipient of several prestigious fellowships and awards, including CSIR Fellowship (India), SMF Fellowship (Singapore), NRC National Academies Fellowship (USA), Nationale Professeur des Universités (France), Fellow of Institute of Nanotechnology (UK) and Fellow of Royal Society of Chemistry (UK).

Stem cell differentiation, Cell patterning, Interface tissue engineering, Biomaterials, Biomolecular delivery.

.

Research approaches for understanding the dynamics and differentiation of stem cells. We use multiple in vivo, ex vivo and in vitro models ranging from Drosophila to mouse to hESC and iPSC to understand the regulation of regeneration. In recent years we have shown that microRNAs and HIF pathway play key roles in regulating adult and embryonic stem cells. Through unbiased Drosophila interaction screen we discovered that increasing the sphingosine-1-phosphate pathway (S1P) has therapeutic effects on muscular dystrophies. Increased S1P levels also show a beneficial effect in adult stem cell based muscle regeneration in mdx, the mouse DMD model. These basic studies are directed towards a long-term goal of stem cell and small molecule based therapeutics.

Dr. Yang received his medical training from Luoyang Medical College, followed by a M.S. Pathophysiology from the Institute of Basic Medical Sciences in Beijing, China. He obtained his Ph.D. degree in Microbiology/Immunology from RFUMS/The Chicago Medical School and postdoctoral training at Northwestern University. Prior to his arrival at the North Carolina Research Campus, he was an Associate Professor of Pathology at the University of Oklahoma Health Sciences Center. Dr. Yang was a recipient of the Career Development Award from the Department of Defense Breast Cancer Research Program. He is also an American Cancer Society Research Scholar.

Dr. Yang's research is focused on molecular and cellular cancer biology. His work has explored E2F-1 mediated oncogenicity; the roles of granyzme and caspases in breast carcinogenesis and therapeutic resistance; communication between p53 and p73 proteins in breast cancer cells; crosstalk between ER and erbB-2 pathways, and phytoestrogen modulated breast cancer prevention. Dr. Yang's current research is on breast cancer etiology and prevention with emphases on the modulation of hormone-growth factor crosstalk, apoptosis and mammary stem cell reprogramming by various genetic and environmental factors.

He is a Professor and Distinguished University Chair in Cellular & Molecular Biology

Research in Dr. McCarrey’s lab is centered on mammalian germ cells and stem cells. Experimental models include the mouse, the baboon, and the opossum. The lab is interested in the epigenetic regulation of cell functions, including determination of cell fates, maintenance of genetic integrity, regulation of gene expression, genomic imprinting, X-chromosome inactivation and meiotic sex chromosome inactivation, methods of assisted reproduction, the evolution of tissue-specific gene expression in mammalian species, and developing the baboon as a model system for testing stem cell-based therapeutic applications.

Professor in Nicolaus Copernicus University in Poland

.

Roberta Di Pietro got the degree in Medicine cum Laude in 1985 and the PhD in Sports Medicine cum Laude in 1988, University of Chieti, Italy. She worked as a visiting scientist in UK at the Biochemistry Department, AFRC, Cambridge; in USA at the Pathology Department, USUHS, Bethesda, and at the Institute of Human Virology, University of Maryland, Baltimore. She currently works at the G. d’Annunzio University of Chieti, Italy, as a Full Professor of Histology. She joined the Editorial Board of Current Pharmaceutical Design as an Executive Guest Editor and since 2010 she was recognized as a Registered Referee for Archives of Ophthalmological Reviews and Reproductive Biology and Endocrinology. She is now author of 168 scientific publications plus international e-bookchapters and Italian textbooks.

Sports Medicine, Histology